IDIOPATHIC PULMONARY FIBROSIS RIN-PF-303 TETON-2
ELIGIBILITY & REQUIREMENTS
- Aged 40 or older
- Confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
WHAT'S INVOLVED
- The trial will run for approximately 56 weeks
- Eight clinic visits to the Institute for Respiratory Health at ICON Cancer Centre, Midland or QEII Medical Centre, Nedlands.
- A full health check by our doctors and nurses
- Reimbursement for travel expenses
- Personalised health care with our doctors and nurses
STUDY OUTLINE
This international research study will test inhaled Treprostinil, an investigational drug.
Inhaled Treprostinil is a full agonist at the prostacyclin receptor (IP) and potently activates the prostaglandin E receptor 2 (EP2) and the prostaglandin D receptor 1 (DP1).
Inhaled Treprostinil is expected to exert antifibrotic effects, presenting a potential novel therapeutic option for IPF patients.
In this research study, you will get either inhaled Treprostinil or placebo, which you will take in addition to your usual IPF medications.
To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0813 or email clinicaltrials@resphealth.uwa.edu.au
PRINCIPAL INVESTIGATOR
Dr David Manners (Midland) and Dr Vidya Navaratnam (Nedlands)
LOCATION
Level 1, 6 Centennial Place, Midland (ICON Cancer Centre)
Level 2, 6 Verdun Street Nedlands (within the Harry Perkins Institute)
THIS CLINICAL TRIAL IS CURRENTLY CLOSED
Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.